A randomized Phase 2 study published on November 1 in The Lancet Oncology has reported longer event-free survival with zamtocabtagene autoleucel than with R-GemOx chemoimmunotherapy in adults with relapsed or refractory large B-cell lymphoma who were ineligible for transplantation. The DALY 2-EU trial addresses a group that has been underrepresented in randomized CAR T-cell evidence and had a median age of 74 years. Zamtocabtagene autoleucel, also called zamto-cel, is an investigational tandem CAR T-cell product directed at both CD20 and CD19.

The open-label trial enrolled patients at 45 centres across 12 European countries. Investigators screened 219 people and randomly assigned 160 in a one-to-one ratio to zamto-cel or rituximab, gemcitabine and oxaliplatin. Participants had histologically confirmed disease after first-line anthracycline-based chemoimmunotherapy, were considered ineligible for transplantation and had an Eastern Cooperative Oncology Group performance-status score of two or lower. Event-free survival was assessed by a masked independent review committee.

At a median follow-up of 17 months, median event-free survival was 6.21 months with zamto-cel and 2.53 months with R-GemOx. The hazard ratio was 0.39, with a 95 percent confidence interval from 0.27 to 0.58 and a p value below 0.0001. The finding corresponds to a 61 percent relative reduction in the risk captured by the composite event-free survival endpoint. That endpoint included progression and other specified treatment-failure events, so it should not be interpreted as an overall-survival result.

The manufacturing model is also notable. Zamto-cel was delivered as a fresh, non-cryopreserved product made in a closed automated system, at 2.5 million CAR T cells per kilogram with dosing capped at 100 kilograms. Median vein-to-vein time was 15 days. A shorter and more predictable manufacturing interval could be relevant for patients with aggressive lymphoma, but the published trial does not by itself establish that the production model can be replicated across every health system or at commercial scale.

High-grade toxicity was common in both groups. Grade 3 or worse treatment-emergent adverse events occurred in 83 percent of evaluable zamto-cel recipients and 86 percent of R-GemOx recipients. Serious adverse events occurred in 41 percent and 66 percent, respectively. Zamto-cel-specific risks included cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Two treatment-related deaths occurred in the zamto-cel group, one from cytokine release syndrome and one from haemophagocytic lymphohistiocytosis, compared with one treatment-related death in the comparator group attributed to lymphoma progression.

Why it matters: anti-CD19 CAR T therapy has changed second-line lymphoma care, but transplant-ineligible patients are often older, have comorbidities or have fewer treatment options. A randomized comparison in this population is more informative than a single-arm response study. Targeting both CD20 and CD19 may also offer a theoretical defence against antigen escape, although this study was not designed to prove that dual targeting is the reason for the observed benefit.

The study has limitations. It was open label, Phase 2 and funded by Miltenyi Biomedicine, the product developer. The comparator reflects a relevant chemoimmunotherapy option, but treatment practice continues to evolve. Race was not reported for 40 percent of participants, limiting assessment of representativeness. Longer follow-up is needed for overall survival, durability, late adverse events and subsequent therapy. The study’s favourable event-free survival result should therefore be weighed alongside acute toxicity, treatment logistics and the absence of mature long-term outcomes.

The authors concluded that the observed risk-benefit profile supports considering zamto-cel as a second-line standard option for this population. Regulatory authorities and health-technology assessment bodies will make their own judgements based on the full evidence package. The publication strengthens the clinical case, but adoption would also depend on approval status, manufacturing access, centre capacity, reimbursement and the ability to identify patients early enough for cell collection and treatment.

A practical next step is to test whether the 15-day median vein-to-vein interval can be maintained outside the trial network. For older patients with rapidly progressing disease, delays can determine whether a planned cellular therapy is delivered at all. Commercial readiness will therefore require more than efficacy data: referral pathways, bridging-treatment protocols, trained centres and dependable local production must work together.